These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38152051)

  • 1. Predictive values of circulating miR-146a and miR-155 for disease activity and clinical response to TNF-α blocking therapy in patients with ankylosing spondylitis.
    Liu L; Hu X
    Int J Rheum Dis; 2024 Jan; 27(1):e15004. PubMed ID: 38152051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis.
    Hu Y; Lou B; Jiang Z; Yu C
    Tohoku J Exp Med; 2023 Jul; 260(3):263-271. PubMed ID: 37081619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis.
    Prajzlerová K; Komarc M; Forejtová Š; Pavelka K; Vencovský J; Šenolt L; Filková M
    Physiol Res; 2021 Apr; 70(2):255-264. PubMed ID: 33676382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.
    Zhou X; Li M
    Mod Rheumatol; 2022 Apr; 32(3):613-618. PubMed ID: 34918117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the expression of miR-146a in peripheral blood mononuclear cells of patients with ankylosing spondylitis and inflammatory factors.
    Wei C; Zhang H; Wei C; Mao Y
    Exp Ther Med; 2017 Nov; 14(5):5027-5031. PubMed ID: 29201209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of miR-146a and IRAK1 gene polymorphisms with ankylosing spondylitis.
    Wang L; Zhang H; Hou NL
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6262-6269. PubMed ID: 32572893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Serum miR-146a and miR-155 as Novel Noninvasive Complementary Biomarkers for Ankylosing Spondylitis.
    Qian BP; Ji ML; Qiu Y; Wang B; Yu Y; Shi W; Luo YF
    Spine (Phila Pa 1976); 2016 May; 41(9):735-42. PubMed ID: 27128253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
    Park JH; Kwon OC; Park MC
    Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA MEG3 inhibits the inflammatory response of ankylosing spondylitis by targeting miR-146a.
    Li Y; Zhang S; Zhang C; Wang M
    Mol Cell Biochem; 2020 Mar; 466(1-2):17-24. PubMed ID: 31894531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
    Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
    Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Response to Tumor Necrosis Value-α Blocker Is Suggested by
    Kim K; Son SM; Goh TS; Pak K; Kim IJ; Lee JS; Kim SJ
    AJR Am J Roentgenol; 2020 Jun; 214(6):1352-1358. PubMed ID: 32286869
    [No Abstract]   [Full Text] [Related]  

  • 16. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.
    Fröhlich F; Micheroli R; Hebeisen M; Kissling S; Bürki K; Exer P; Bräm R; Niedermann K; Möller B; Nissen MJ; Kyburz D; Andor M; Distler O; Scherer A; Ciurea A
    Clin Rheumatol; 2023 May; 42(5):1267-1274. PubMed ID: 36574181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
    Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
    Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.